Diabetic vitrectomy: Risks, prognosis, future trends

Current Opinion in Ophthalmology

Volumn 17, Issue 3, 2006, Pages 281-285

  Mason III, John O ^a,b   Colagross, Cheri T ^b   Vail, Rachel ^b  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b Retina Consultants Alabama   (United States)

Author keywords

Diabetic macular edema; Diabetic retinal detachment; Diabetic retinopathy; Macular ischemia; Vitrectomy; Vitreous hemorrhage

Indexed keywords

GLUCOSE;

CILIARY DISK; CRYOTHERAPY; DIABETIC RETINOPATHY; EYE DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INJURY; LASER; METABOLISM; NEUROPROTECTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RETINA DISEASE; RETINA ISCHEMIA; RETINA MACULA EDEMA; REVIEW; RISK ASSESSMENT; SCLEROTOMY; VITRECTOMY; VITREOUS HEMORRHAGE; WOUND HEALING;

DIABETIC RETINOPATHY; HUMANS; MACULAR EDEMA; MACULAR EDEMA, CYSTOID; PROGNOSIS; RISK FACTORS; VITRECTOMY;

EID: 33748189291     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.icu.0000193098.28798.18     Document Type: Review

References (46)

1. Mason JO, Colagross CT, Haleman T, et al. Visual outcome and risk factors for light perception and no light perception vision after vitrectomy for diabetic retinopathy. Am J Ophthalmol 2005; 140:231-235. Our study revealed that preoperative and postoperative INV, postoperative macular ischemia, and postoperative vitreous hemorrhage were strong risk factors for severe vision loss in diabetic PPV. Overall visual outcomes continue to improve.
2. Helbig H, Sutter FKP. Surgical treatment of diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2004; 242:704-709.
3. Kempen JH, O'Colmain BJ, Leske MC, et al. for the Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the US. Arch Ophthalmol 2004; 122:552-563.
4. Centers for Disease Control and Prevention. Blindness caused by diabetes - Massachusetts 1987-1994. MMWR Morb Mortal Wkly Rep 1996; 45:937-941.
5. World Health Organization, International Diabetes Federation. Diabetes action now: a joint initiative of the World Health Organization and International Diabetes Federation. Geneva, Switzerland: World Health Organization; 2004.
6. Sharma S, Hollands H, Brown GC, et al. The cost effectiveness of early vitrectomy for the treatment of vitreous hemorrhage in diabetic retinopathy. Curr Opin Ophthalmol 2001; 12:230-234.
7. Ishida M, Takeuchi S. Long-term results of vitrectomy for complications of proliferative diabetic retinopathy. Jpn J Ophthalmol 2002; 46:117-122.
8. Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol 2004; 15:508-518.
9. Cunha-Vaz JG. Medical treatments of retinopathy of type-2 diabetes. Ophthalmologica 2004; 218:291-296.
10. Boyd SR, Zachary I, Chakravarthy U, et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central retinal vein occlusion. Arch Ophthalmol 2002; 120:1644-1650.
11. Frank RN. Medical progress: diabetic retinopathy. N Engl J Med 2004; 350:48-58.
12. Porta M, Allione A. Current approaches and perspectives in the medical treatment of diabetic retinopathy. Pharmacol Ther 2004; 103:167-177.
13. Yamashita H. Pathogenesis of diabetic retinopathy and strategy to develop new therapeutic modalities. Ophthalmologica 2004; 218:19-28.
14. Colucciello M. Diabetic retinopathy: control of systemic factors preserves vision. Postgrad Med 2004; 116:57-64.
15. Sjolie AK, Moller F. Medical management of diabetic retinopathy. Diabetes UK. Diabetic Med 2004; 21:666-672.
16. Machemer R, Buettner H, Norton RWD, et al. Vitrectomy: a pars plana approach. Trans Am Acad Ophthalmol Otolaryngol 1971; 75:813-820.
17. Diabetic Retinopathy Vitrectomy Study Research Group. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study Report #1. Ophthalmology 1985; 92:492-502.
18. Smiddy WE, Feuer W, Irvine WD, et al. Vitrectomy for complications of proliferative diabetic retinopathy: functional outcomes. Ophthalmology 1995; 102:1688-1695.
19. Thompson JT, Auer CL, deBustros S, et al. Prognostic indicators of success and failure in vitrectomy for diabetic retinopathy. Ophthalmology 1986; 93:503-506.
20. Yang CM. Surgical treatment for diabetic retinopathy: five year experience. J Formos Med Assoc 1998; 97:477-484.
21. Thompson MJ, Ip MS. Diabetic macular edema: a review of past, present, and future therapies. Int Ophthalmol Clin 2004; 44:51-67.
22. Lahey JM, Francis RR, Kearney JJ, et al. Combining phacoemulsification and vitrectomy in patients with proliferative diabetic retinopathy. Curr Opin Ophthalmol 2004; 15:192-196.
23. Sullu Y, Hamidova R, Beden U, et al. Effects of pars plana vitrectomy on retrobulbar haemodynamics in diabetic retinopathy. Clin Exp Ophthalmol 2005; 33:246-251.
24. Imamara Y, Kamei M, Minami M, et al. Heparin-assisted removal of clotting preretinal hemorrhage during vitrectomy for proliferative diabetic retinopathy. Retina 2005; 25:793-795.
25. Treumer F, Bunse A, Rudolf M, et al. Pars plana vitrectomy, phacoemulsification and intraocular lens implantation: comparison of clinical complications in a combined versus two-step surgical approach. Graefes Arch Clin Exp Ophthalmol 2005; 3:1-8. This was a well written article revealing the safety of combined cataract extraction and PPV.
26. Kono T, Shiga S, Takesue Y, et al. Long-term results of pars plana vitrectomy combined with filtering surgery for neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2005; 36:211-216.
27. Lane RG, Jumper JM, Nasir MA, et al. A prospective, open-label, dose-escalating study of low molecular weight heparin during repeat vitrectomy for PVR and severe diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2005; 243:701-705.
28. Quiroz-Mercado H, Guerrero-Naranjo J, Agurto-Rivera R, et al. Perfluorocarbon-perfused vitrectomy: a new method for vitrectomy - a safety and feasibility study. Graefes Arch Clin Exp Ophthalmol 2005; 243:551-562.
29. Eckardt C. Transconjunctival sutureless 23-gauge vitrectomy. Retina 2005; 25:208-211.
30. Soto-Pedre E, Hernaez-Ortega MD, Vazquez JA. Risk factors for postoperative hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmic Epidemiol 2005; 12:335-341.
31. Hershberger VS, Ausburger JJ, Hutchins RK, et al. Fibrovascular ingrowth at sclerotomy sites in vitrectomized diabetic eyes with recurrent vitreous hemorrhage. Ophthalmologica 2004; 111:1215-1221.
32. Yeh P, Yang C, Yang C, et al. Cryotherapy of the anterior retina and sclerotomy sites in diabetic vitrectomy to prevent recurrent vitreous hemorrhage. Ophthalmologica 2005; 112:2095-2102. This study showed that most postoperative vitreous hemorrhage is secondary to fibrovascular ingrowth and cryotherapy may lead to less postoperative vitreous hemorrhage.
33. Zaninetti M, Petropoulos IK, Pournaras CJ. Proliferative diabetic retinopathy: vitreo-retinal complications are often related to insufficient retinal photocoagulation [in French]. J Fr Ophthalmol 2005; 28:381-384. This study found that increased photocoagulation during surgery can reduce the risk of regrowth of fibrovascular membranes.
34. Ramezani AR, Ahmadieh H, Ghaseminejad AK, et al. Effect of tranexamic acid on early postvitrectomy diabetic hemorrhage: a randomized clinical trial. Br J Ophthalmol 2005; 89:1041-1044.
35. Jahn CE, Topfner Von Schutz K, Richter J, et al. Improvement of visual acuity in eyes with diabetic macular edema after treatment with pars plana vitrectomy. Ophthalmologica 2004; 218:378-384.
36. Pendergast SC. Vitrectomy for diabetic macular edema associated with a taut premacular posterior hyaloid. Curr Opin Ophthalmol 1998; 9:71-75.
37. Recchia FM, Ruby AJ, Carvalho Recchia CA. Pars plana vitrectomy with removal of the internal limiting membrane in the treatment of persistent diabetic macular edema. Am J Ophthalmol 2005; 139:447-454.
38. Kimura T, Kiryu J, Nishiwaki H, et al. Efficacy of surgical removal of the internal limiting membrane in diabetic cystoid macular edema. Retina 2005; 25:454-461.
39. Stolba U, Binder S, Gruber D, et al. B. Vitrectomy for persistent diabetic macular edema. Am J Ophthalmol 2005; 140:295-301. A randomized controlled trial showing that PPV and ILM peeling lead to better vision and foveal thickness than a control group.
40. Yanyali A, Nohutcu AF, Horozoglu F, et al. Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthalmol 2005; 139:795-801.
41. Mason JO, Roberts BW, Emond TL, et al. Visual outcomes and recurrence rates of macular pucker surgery with and without internal limiting membrane peeling. Clin Surg Ophthalmol 2004; 22:6-10.
42. Yamamoto S, Yamamoto T, Ogata K, et al. Morphological and functional changes of the macula after vitrectomy and creation of posterior vitreous detachment in eyes with diabetic macular edema. Doc Ophthalmol 2004; 109:249-253.
43. Yamamoto T, Hitani K, Sato Y, et al. Vitrectomy for diabetic macular edema with and without internal limiting membrane removal. Ophthalmologica 2005; 219:206-213.
44. Thomas D, Bunce C, Moorman D, Laidlaw DA. A randomized controlled feasibility trial of vitrectomy versus laser for diabetic macular edema. Br J Ophthalmol 2005; 89:81-86. This prospective randomized trial showed no benefit of PPV compared with laser for DME.
45. Patel JI, Hykin PG, Schadt M, et al. Pars plana vitrectomy for diabetic macular edema: OCT and functional correlations. Eye 2005 [Epub ahead of print]. A well conducted study showing structural and functional macular improvement after PPV for DME.
46. Sharma S, Oliver-Fernandez A, Liu W, et al. The impact of diabetic retinopathy on health-related quality of life. Curr Opin Ophthalmol 2005; 16:155-159.